May 9, 2024- Premier, Inc. announced a strategic partnership with AstraZeneca called Uncover CKD – Care Collective aiming to identify patients with undiagnosed clinical chronic kidney disease (CKD); raise awareness of undiagnosed CKD among healthcare providers; and inform U.S. health systems that want to improve or develop and implement their strategies for CKD diagnosis, treatment and management.
In the U.S., more than 37 million adults have CKD, and the prevalence is rising. Of these adult patients, 90 percent do not know they have CKD. Total inflation-adjusted Medicare expenditures for patients with end-stage renal disease increased to $53 billion in 2019. Among CKD patients, the cost of preventable hospitalizations is $79 million.
Through collaborative initiatives and scalable solutions from across the Premier enterprise, including its PINC AI™ technology and services platform, the Uncover CKD – Care Collective is addressing undiagnosed and rising CKD and the resulting economic burden to the U.S. healthcare system. The partnership with AstraZeneca demonstrates a commitment to implement and learn about innovative approaches to driving optimization of guideline-directed medical therapy for patients.